Deals channel feed

Re­silience nets an­oth­er deal, this time with bil­lion­aire’s can­cer re­search cen­ter

4 years ago
Manufacturing

Fol­low­ing tie-up with Sanofi, transat­lantic AI firm se­cures lat­est Big Phar­ma deal in nine-fig­ure Bris­tol My­ers pact

4 years ago
AI

Mod­er­na’s Cin­derel­la sto­ry is get­ting a scary rewrite on Wall Street, and a top an­a­lyst points to one path to a hap­py end­ing

4 years ago
Bioregnum

FTC opens in­ves­ti­ga­tion in­to largest PBM­s' an­ti­com­pet­i­tive prac­tices

4 years ago
Pharma

EQT's in­vest­ment arm and Mubadala ink $3B deal for med­ical freight and stor­age com­pa­ny

4 years ago
Pharma
Manufacturing

Fol­low­ing Vounatsos' an­nounced de­par­ture, Bio­gen part­ners with pri­vate Cana­di­an biotech for oral Parkin­son's treat­ment

4 years ago

Fol­low­ing deep cuts, Yu­man­i­ty strikes a deal to sell drugs to J&J, hands the keys to Genen­tech-part­nered Kine­ta

4 years ago
People

Boehringer In­gel­heim inks deal for tar­get­ed can­cer an­ti­bod­ies from Sin­ga­pore re­search org

4 years ago
R&D

Bris­tol My­ers jumps in­to the M&A game with a $4B on­col­o­gy buy­out. And weary biotech an­a­lysts could­n't be any hap­pi­er

4 years ago

Re­gen­eron inks $1B+ deal for glob­al rights to Sanofi-part­nered PD-1 Lib­tayo

4 years ago
Pharma

Im­mat­ics imag­ines broad­er CAR-T pipeline with an­oth­er Bris­tol My­ers pact and ad­di­tion to 2019 TCR deal

4 years ago
Cell/Gene Tx

Once a GSK hope­ful for heart dis­ease, an in­hibitor class makes a come­back in Alzheimer's deal

4 years ago

Four years af­ter Roche deal, lit­tle gly­co-fo­cused biotech lands new dis­cov­ery deal with Astel­las

4 years ago

Long af­ter the block­buster shoutouts fad­ed to a whis­per, Ther­a­peu­tic­sMD gets an M&A deal

4 years ago

GSK bets $3.3B on a buy­out, jump­ing in­to a block­buster show­down with Pfiz­er and Mer­ck

4 years ago

Af­ter $60M Ver­tex deal, group of Cat­a­lyst share­hold­ers claims biotech could’ve sold as­sets three years ago

4 years ago

Tak­ing an­oth­er shot at mR­NA glo­ry, Cure­Vac inks on­col­o­gy pact while keep­ing up with Covid work

4 years ago

An­tios' HBV col­lab axed af­ter clin­i­cal hold, but biotech be­lieves safe­ty in­ci­dent is not treat­ment-re­lat­ed

4 years ago
FDA+

Life sci­ences de­vel­op­er Bio­Med Re­al­ty buys San Fran­cis­co ho­tel for $75M — re­port

4 years ago

At the cusp of NDA fil­ing for lead an­tibi­ot­ic, As­traZeneca spin­out goes pri­vate at a frac­tion of IPO price

4 years ago

As GSK-part­nered Covid an­ti­body racks up glob­al sales, Vir ax­es WuXi deal and grabs back Chi­na rights

4 years ago
China
Coronavirus

Al­con takes a crack at multi­bil­lion-dol­lar dry eye mar­ket, picks up 2 drugs from Langer spin­out

4 years ago

All Blue's $733M bid to ac­quire Zymeworks turns hos­tile as board bat­tles back — af­ter a biotech celebri­ty jumps in

4 years ago

Bay­er sounds re­treat from a $670 mil­lion CAR-T pact in the wake of a pa­tient death

4 years ago
R&D
First page Previous page 58596061626364 Next page Last page
A service from the Financial Times